# Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02916706` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02916706](<https://clinicaltrials.gov/study/NCT02916706>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02916706

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.

## Technical summary

Registry record NCT02916706. Quadruple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2018-08-14 (actual). Results posted on 2022-01-28.

## Key facts

- Design: Interventional study; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 254 participants (enrolled count; ClinicalTrials.gov record NCT02916706, source copy `cardio:ctgov-nct02916706-2026-01-06`, retrieved 2026-10-26)
- Start date: 2016-09 (registry gives no type) (ClinicalTrials.gov record NCT02916706, source copy `cardio:ctgov-nct02916706-2026-01-06`, retrieved 2026-10-26)
- Primary completion: 2018-08-14 (actual) (ClinicalTrials.gov record NCT02916706, source copy `cardio:ctgov-nct02916706-2026-01-06`, retrieved 2026-10-26)
- Completion: Not reported
- Results first posted: 2022-01-28 (ClinicalTrials.gov record NCT02916706, source copy `cardio:ctgov-nct02916706-2026-01-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02916706, source copy `cardio:ctgov-nct02916706-2026-01-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02916706-2026-01-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Teneligliptin 20mg
- Intervention (Drug): Placebo
- Lead sponsor: Tanabe Pharma Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Tanabe Pharma Corporation (`cardio:org-tanabe-pharma-corporation`)

## Provenance

Content hash: 5e251d65cccf6b52f7916c3681669ac1f5dfbfa7de0d3ea18c959ab478db4804
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
